Please assess the completion status of the following clinical trial:

Trial Title: Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a confirmed S. mansoni infection (positive POC-CCA test result and at least one positive out of triplicate Kato-Katz thick smears)~* Subject is aged between 5 and 18 years and otherwise in good health~* Subject has received no recent praziquantel treatment in the past month~* Subject has provided oral assent and provided written informed consent signed by parents/legal guardian~* Subject is able and willing to provide multiple stool and urine samples during study~Exclusion Criteria:~* Known allergy to study medication (i.e. praziquantel and albendazole)~* Pregnancy~* Lactating

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Control group (A) (Type: ACTIVE_COMPARATOR): 1x praziquantel: Children assigned to group A receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive no further treatment until the final visit (week 8).
- Intervention group (B) (Type: EXPERIMENTAL): 4x praziquantel: Children assigned to group B receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive three consecutive praziquantel treatments (40 mg/kg) in the following six weeks with 2 weeks intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).